Reuters logo
BRIEF-TG Therapeutics says successful outcome from analysis in UNITY-CLL trial
May 23, 2017 / 11:47 AM / 7 months ago

BRIEF-TG Therapeutics says successful outcome from analysis in UNITY-CLL trial

May 23 (Reuters) - TG Therapeutics Inc

* TG Therapeutics Inc. announces successful outcome from pre-planned interim analysis by independent DSMB in the UNITY-CLL Phase 3 trial

* TG Therapeutics Inc - found no safety concerns and recommended continuation of enrollment without modification in trial

* Says study will now continue enrollment in a 1:1 ratio to only two combination arms

* Says given current rate of enrollment, we are now targeting complete enrollment by year end

* Says expect to report pivotal overall response rate (orr) data in Q3 of 2018

* Says DSMB recommended company cease enrollment into single agent arms Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below